<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762994</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-085-2</org_study_id>
    <nct_id>NCT02762994</nct_id>
  </id_info>
  <brief_title>International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>International Multi-center Comparative Randomized Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-085-2 is a next step in clinical investigation of BCD-085. BCD-085 is a monoclonal&#xD;
      antibody to interleukin 17. During BCD-085-2 trial patients with moderate to severe plaque&#xD;
      psoriasis, in whom poor response to previous treatment including UV-therapy and biologic&#xD;
      drugs was registered, will receive 40, 80 or 120 mg of BCD-085 subcutaneously at weeks 0, 1,&#xD;
      2, 4, 6, 8, 10. Efficacy and safety parameters will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With PASI 75 Response After 12 Weeks of Therapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). The proportion of patients with PASI 75 was defined as patients achieving 75% or more improvement at Week 12 of therapy with BCD-085 from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With PASI75 Response After 4 and 8 Weeks of Therapy</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). The proportion of patients with PASI 75 was defined as patients achieving 75% or more improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With PASI50 and PASI90 Response After 4, 8 and 12 Weeks of Therapy</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
    <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). The proportion of patients with PASI 50 and PASI 90 was defined as patients achieving 50% or more and 90% or more improvement from baseline, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in PASI Score After 4, 8 and 12 Weeks of Therapy With BCD-085</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
    <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease).&#xD;
Relative (percentage) change in PASI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in BSA After 4, 8 and 12 Weeks of Therapy With BCD-085</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
    <description>The area of skin affected by psoriasis (BSA) is estimated with the palm rule. The area of the human palm without fingers corresponds to about 1% of the body surface.&#xD;
Relative (percentage) from baseline is calculated as &quot;100 x (baseline value - time point t value) / (baseline value)&quot;. If the value decreases from baseline it means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in NAPSI Score After 12 Weeks of Therapy With BCD-085</measure>
    <time_frame>Week 12</time_frame>
    <description>The NAPSI is used to assign a score to each nail involved, which can vary from 0 to 8. In this study, nail involvement will be assessed only for hands, so the total index of all nails can be from 0 to 80 (only hands). A negative change from baseline indicates improvement.&#xD;
Relative (percentage) change in NAPSI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Severity of Pruritus Assessed by Visual Analog Scale After 1, 4, 8 and 12 Weeks of Treatment With BCD-085</measure>
    <time_frame>Week 1, Week 4, Week 8, Week 12</time_frame>
    <description>Mean change in severity of pruritus assessed by visual analog scale (from 0 (no itch) to 100 mm (unbearable itch)) after 1, 4, 8 and 12 weeks of treatment with BCD-085</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With sPGA Response After 4, 8, 12 Weeks of Treatment With BCD-085</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
    <description>The sPGA scale is used to assess the psoriatic lesions in a certain patient from 0 (clear) to 5 (very severe). Within each area, the severity is estimated by three criteria (induration, desquamation, and erythema).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Quality of Life Assessed by SF-36 After 4, 8 and 12 Weeks of Treatment With BCD-085</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
    <description>SF-36 is a standardized participant-administered measure designed to evaluate 8 domains of functional health and well being with 2 components (physical health score [PH] and mental component score [MH]). Both scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Quality of Life Assessed by DLQI After 4, 8 and 12 Weeks of Treatment With BCD-085</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
    <description>The Dermatology Life Quality Index (DLQI) is a 10-item self-reported survey, which addresses feelings, daily activities, leisure, work, school, personal relationships, and treatment. Each question was assessed using a 3-point scale, where score 3 means &quot;very much&quot;, score 2 means &quot;a lot&quot;, score 1 - &quot;a little&quot;, and score 0 - &quot;not at all&quot;. If more than two questions were left unanswered, the questionnaire was considered invalid. A total score was calculated by summing the score of all items (total maximum score is 30; total minimum score is 0). The higher score representing greater health-related quality of life impairment.&#xD;
The mean score change was estimated as the difference between the DLQI at baseline and at the assessed visit (the baseline score was subtracted from the visit score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE/SAE</measure>
    <time_frame>14 weeks</time_frame>
    <description>Number of participants with AEs and SAEs was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Local Reactions</measure>
    <time_frame>14 weeks</time_frame>
    <description>Number of participants with local reactions was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE/SAE Grade 4 CTCAE 4.03</measure>
    <time_frame>14 weeks</time_frame>
    <description>Number of participants with AEs/SAEs grade 4 CTCAE 4.03 was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Withdrawal Due to AE/SAE</measure>
    <time_frame>14 weeks</time_frame>
    <description>Number of participants who withdrew due to AEs/SAEs was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>BCD-085, 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-085, 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-085, 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCD-085</intervention_name>
    <arm_group_label>BCD-085, 120 mg</arm_group_label>
    <arm_group_label>BCD-085, 40 mg</arm_group_label>
    <arm_group_label>BCD-085, 80 mg</arm_group_label>
    <other_name>monoclonal antibody to interleukin 17</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age between 18 and 65 years&#xD;
&#xD;
          -  Diagnosis of plaque psoriasis with stable course of the disease during last 6 months&#xD;
             prior to enrollment in the study.&#xD;
&#xD;
          -  Patient have had at least 1 course of phototherapy or systemic therapy of psoriasis or&#xD;
             are candidates for such treatment.&#xD;
&#xD;
          -  BSA affected by psoriasis ≥ 10%, PASI score ≥ 12, sPGA score ≥ 3.&#xD;
&#xD;
          -  If patient have had biologic therapy for at least 3 months, there was no positive&#xD;
             results of such treatment or patient revealed intolerance to the drug. This therapy&#xD;
             must be discontinued at least 12 weeks before enrollment in the study.&#xD;
&#xD;
          -  Female patients have negative urine pregnancy test.&#xD;
&#xD;
          -  Patient has no history of tuberculosis.&#xD;
&#xD;
          -  Patients have negative results of Diaskintest.&#xD;
&#xD;
          -  Patient has no history of alcohol or drug abuse.&#xD;
&#xD;
          -  Patients are able to perform all procedures planed by protocol.&#xD;
&#xD;
          -  Patients are ready for contraception with reliable methods starting 2 weeks before&#xD;
             entering the study, and up to 4 weeks after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,&#xD;
             medication-induced psoriasis, or other skin conditions at the time of the screening&#xD;
             visit (e.g., eczema) that would interfere with evaluations of the effect of&#xD;
             investigational product on psoriasis.&#xD;
&#xD;
          -  Previous receipt of anti-interleukin 17 drugs or anti-interleukin 17 receptor drugs.&#xD;
&#xD;
          -  Prior use of two or more biologics to tumor necrosis factor alfa.&#xD;
&#xD;
          -  Prior use of two or more biologics to other targets.&#xD;
&#xD;
          -  Previous receipt of monoclonal antibodies if they were cancelled less that in 12 weeks&#xD;
             before signing informed consent.&#xD;
&#xD;
          -  Patient is taking corticosteroids for up to 4 weeks in a dose more than 10 mg&#xD;
             (recalculated to prednisolone) before signing informed consent and during screening,&#xD;
             or in a dose less than 10 mg (recalculated to prednisolone) if it was not stable.&#xD;
&#xD;
          -  Prior use of disease-modifying drugs including methotrexate, sulfasalazin and&#xD;
             cyclosporin for up to 4 weeks before signing informed consent, if their dose was not&#xD;
             stable for up to 4 weeks before signing informed consent and during screening Prior&#xD;
             use of live or attenuated vaccines for up to 8 weeks before signing informed consent.&#xD;
&#xD;
          -  Prior use of phototherapy including selective phototherapy and photochemotherapy for&#xD;
             up to 4 weeks before signing informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JCS BIOCAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIOCAD</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Strelna</state>
        <zip>198515</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <results_first_submitted>July 17, 2020</results_first_submitted>
  <results_first_submitted_qc>February 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2021</results_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interleukin 17</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02762994/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02762994/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-085, 40 mg</title>
          <description>Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
        </group>
        <group group_id="P2">
          <title>BCD-085, 80 mg</title>
          <description>Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
        </group>
        <group group_id="P3">
          <title>BCD-085, 120 mg</title>
          <description>Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Provided information only of the patients included in the efficacy assessment (114 subjects).</population>
      <group_list>
        <group group_id="B1">
          <title>BCD-085, 40 mg</title>
          <description>Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
        </group>
        <group group_id="B2">
          <title>BCD-085, 80 mg</title>
          <description>Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
        </group>
        <group group_id="B3">
          <title>BCD-085, 120 mg</title>
          <description>Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.50" lower_limit="32.00" upper_limit="50.00"/>
                    <measurement group_id="B2" value="35.00" lower_limit="29.00" upper_limit="45.00"/>
                    <measurement group_id="B3" value="45.00" lower_limit="35.00" upper_limit="54.00"/>
                    <measurement group_id="B4" value="41.50" lower_limit="32.00" upper_limit="48.00"/>
                    <measurement group_id="B5" value="40.50" lower_limit="32.00" upper_limit="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.00" lower_limit="70.00" upper_limit="90.00"/>
                    <measurement group_id="B2" value="80.50" lower_limit="65.00" upper_limit="96.00"/>
                    <measurement group_id="B3" value="87.25" lower_limit="76.00" upper_limit="100.00"/>
                    <measurement group_id="B4" value="77.55" lower_limit="64" upper_limit="85"/>
                    <measurement group_id="B5" value="82.00" lower_limit="70.00" upper_limit="93.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178.50" lower_limit="170.00" upper_limit="182.00"/>
                    <measurement group_id="B2" value="173.00" lower_limit="166.00" upper_limit="178.00"/>
                    <measurement group_id="B3" value="177.00" lower_limit="169.40" upper_limit="182.00"/>
                    <measurement group_id="B4" value="175.00" lower_limit="164.00" upper_limit="182.00"/>
                    <measurement group_id="B5" value="176.00" lower_limit="168.00" upper_limit="182.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="26"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.81" lower_limit="23.70" upper_limit="29.09"/>
                    <measurement group_id="B2" value="26.85" lower_limit="23.62" upper_limit="29.59"/>
                    <measurement group_id="B3" value="29.72" lower_limit="24.15" upper_limit="31.94"/>
                    <measurement group_id="B4" value="24.95" lower_limit="22.95" upper_limit="30.12"/>
                    <measurement group_id="B5" value="26.23" lower_limit="23.73" upper_limit="30.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Women With Child Bearing Potential</title>
          <population>Provided information only of the women enrolled in the study (35 subjects).</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With PASI 75 Response After 12 Weeks of Therapy</title>
        <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). The proportion of patients with PASI 75 was defined as patients achieving 75% or more improvement at Week 12 of therapy with BCD-085 from baseline.</description>
        <time_frame>12 weeks</time_frame>
        <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With PASI 75 Response After 12 Weeks of Therapy</title>
          <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). The proportion of patients with PASI 75 was defined as patients achieving 75% or more improvement at Week 12 of therapy with BCD-085 from baseline.</description>
          <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With PASI75 Response After 4 and 8 Weeks of Therapy</title>
        <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). The proportion of patients with PASI 75 was defined as patients achieving 75% or more improvement from baseline.</description>
        <time_frame>Week 4, Week 8</time_frame>
        <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With PASI75 Response After 4 and 8 Weeks of Therapy</title>
          <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). The proportion of patients with PASI 75 was defined as patients achieving 75% or more improvement from baseline.</description>
          <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With PASI50 and PASI90 Response After 4, 8 and 12 Weeks of Therapy</title>
        <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). The proportion of patients with PASI 50 and PASI 90 was defined as patients achieving 50% or more and 90% or more improvement from baseline, respectively.</description>
        <time_frame>Week 4, Week 8, Week 12</time_frame>
        <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With PASI50 and PASI90 Response After 4, 8 and 12 Weeks of Therapy</title>
          <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). The proportion of patients with PASI 50 and PASI 90 was defined as patients achieving 50% or more and 90% or more improvement from baseline, respectively.</description>
          <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proportion of PASI 50 achievers, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of PASI 50 achievers,Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of PASI 50 achievers,Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of PASI 90 achievers, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of PASI 90 achievers, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of PASI 90 achievers, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in PASI Score After 4, 8 and 12 Weeks of Therapy With BCD-085</title>
        <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease).&#xD;
Relative (percentage) change in PASI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value)</description>
        <time_frame>Week 4, Week 8, Week 12</time_frame>
        <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in PASI Score After 4, 8 and 12 Weeks of Therapy With BCD-085</title>
          <description>The PASI allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease).&#xD;
Relative (percentage) change in PASI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value)</description>
          <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean percentage change from baseline in PASI score at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.309" spread="23.423"/>
                    <measurement group_id="O2" value="58.855" spread="27.382"/>
                    <measurement group_id="O3" value="59.524" spread="26.251"/>
                    <measurement group_id="O4" value="26.277" spread="25.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean percentage change from baseline in PASI score at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.148" spread="17.751"/>
                    <measurement group_id="O2" value="78.883" spread="20.350"/>
                    <measurement group_id="O3" value="85.012" spread="16.389"/>
                    <measurement group_id="O4" value="36.512" spread="29.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean percentage change from baseline in PASI score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.698" spread="15.670"/>
                    <measurement group_id="O2" value="88.682" spread="13.607"/>
                    <measurement group_id="O3" value="92.771" spread="11.426"/>
                    <measurement group_id="O4" value="45.495" spread="36.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in BSA After 4, 8 and 12 Weeks of Therapy With BCD-085</title>
        <description>The area of skin affected by psoriasis (BSA) is estimated with the palm rule. The area of the human palm without fingers corresponds to about 1% of the body surface.&#xD;
Relative (percentage) from baseline is calculated as &quot;100 x (baseline value - time point t value) / (baseline value)&quot;. If the value decreases from baseline it means improvement.</description>
        <time_frame>Week 4, Week 8, Week 12</time_frame>
        <population>The efficacy population comprised of 114 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in BSA After 4, 8 and 12 Weeks of Therapy With BCD-085</title>
          <description>The area of skin affected by psoriasis (BSA) is estimated with the palm rule. The area of the human palm without fingers corresponds to about 1% of the body surface.&#xD;
Relative (percentage) from baseline is calculated as &quot;100 x (baseline value - time point t value) / (baseline value)&quot;. If the value decreases from baseline it means improvement.</description>
          <population>The efficacy population comprised of 114 patients.</population>
          <units>percentage of BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean percentage change from baseline in BSA at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.046" spread="31.699"/>
                    <measurement group_id="O2" value="45.610" spread="30.987"/>
                    <measurement group_id="O3" value="39.948" spread="35.084"/>
                    <measurement group_id="O4" value="13.692" spread="22.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean percentage change from baseline in BSA at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.479" spread="29.547"/>
                    <measurement group_id="O2" value="67.233" spread="30.765"/>
                    <measurement group_id="O3" value="68.516" spread="33.657"/>
                    <measurement group_id="O4" value="24.075" spread="32.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean percentage change from baseline in BSA at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.888" spread="24.699"/>
                    <measurement group_id="O2" value="82.811" spread="19.751"/>
                    <measurement group_id="O3" value="82.074" spread="29.460"/>
                    <measurement group_id="O4" value="36.912" spread="39.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in NAPSI Score After 12 Weeks of Therapy With BCD-085</title>
        <description>The NAPSI is used to assign a score to each nail involved, which can vary from 0 to 8. In this study, nail involvement will be assessed only for hands, so the total index of all nails can be from 0 to 80 (only hands). A negative change from baseline indicates improvement.&#xD;
Relative (percentage) change in NAPSI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value)</description>
        <time_frame>Week 12</time_frame>
        <population>This analysis did not include patients who had no nail psoriasis at baseline and who had no worsening of nail psoriasis during the study (patients who had NAPSI = 0 at baseline and at Week 12). The final population for NAPSI assessment comprised 66 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in NAPSI Score After 12 Weeks of Therapy With BCD-085</title>
          <description>The NAPSI is used to assign a score to each nail involved, which can vary from 0 to 8. In this study, nail involvement will be assessed only for hands, so the total index of all nails can be from 0 to 80 (only hands). A negative change from baseline indicates improvement.&#xD;
Relative (percentage) change in NAPSI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value)</description>
          <population>This analysis did not include patients who had no nail psoriasis at baseline and who had no worsening of nail psoriasis during the study (patients who had NAPSI = 0 at baseline and at Week 12). The final population for NAPSI assessment comprised 66 patients.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.204" spread="45.347"/>
                    <measurement group_id="O2" value="47.095" spread="29.800"/>
                    <measurement group_id="O3" value="66.370" spread="29.455"/>
                    <measurement group_id="O4" value="7.828" spread="36.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Severity of Pruritus Assessed by Visual Analog Scale After 1, 4, 8 and 12 Weeks of Treatment With BCD-085</title>
        <description>Mean change in severity of pruritus assessed by visual analog scale (from 0 (no itch) to 100 mm (unbearable itch)) after 1, 4, 8 and 12 weeks of treatment with BCD-085</description>
        <time_frame>Week 1, Week 4, Week 8, Week 12</time_frame>
        <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Severity of Pruritus Assessed by Visual Analog Scale After 1, 4, 8 and 12 Weeks of Treatment With BCD-085</title>
          <description>Mean change in severity of pruritus assessed by visual analog scale (from 0 (no itch) to 100 mm (unbearable itch)) after 1, 4, 8 and 12 weeks of treatment with BCD-085</description>
          <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes in the intensity of pruritus, Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.600" spread="23.562"/>
                    <measurement group_id="O2" value="-25.367" spread="29.678"/>
                    <measurement group_id="O3" value="-26.071" spread="29.034"/>
                    <measurement group_id="O4" value="-14.269" spread="34.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in the intensity of pruritus, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.767" spread="24.996"/>
                    <measurement group_id="O2" value="-33.700" spread="31.682"/>
                    <measurement group_id="O3" value="-43.214" spread="30.927"/>
                    <measurement group_id="O4" value="-13.269" spread="32.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in the intensity of pruritus, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.533" spread="25.871"/>
                    <measurement group_id="O2" value="-35.633" spread="34.927"/>
                    <measurement group_id="O3" value="-47.304" spread="33.431"/>
                    <measurement group_id="O4" value="-15.538" spread="34.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in the intensity of pruritus, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.533" spread="26.432"/>
                    <measurement group_id="O2" value="-40.700" spread="30.563"/>
                    <measurement group_id="O3" value="-48.214" spread="30.839"/>
                    <measurement group_id="O4" value="-18.269" spread="34.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With sPGA Response After 4, 8, 12 Weeks of Treatment With BCD-085</title>
        <description>The sPGA scale is used to assess the psoriatic lesions in a certain patient from 0 (clear) to 5 (very severe). Within each area, the severity is estimated by three criteria (induration, desquamation, and erythema).</description>
        <time_frame>Week 4, Week 8, Week 12</time_frame>
        <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With sPGA Response After 4, 8, 12 Weeks of Treatment With BCD-085</title>
          <description>The sPGA scale is used to assess the psoriatic lesions in a certain patient from 0 (clear) to 5 (very severe). Within each area, the severity is estimated by three criteria (induration, desquamation, and erythema).</description>
          <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sPGA score 0 or 1, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sPGA score 0 or 1, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sPGA score 0 or 1, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Quality of Life Assessed by SF-36 After 4, 8 and 12 Weeks of Treatment With BCD-085</title>
        <description>SF-36 is a standardized participant-administered measure designed to evaluate 8 domains of functional health and well being with 2 components (physical health score [PH] and mental component score [MH]). Both scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.</description>
        <time_frame>Week 4, Week 8, Week 12</time_frame>
        <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Quality of Life Assessed by SF-36 After 4, 8 and 12 Weeks of Treatment With BCD-085</title>
          <description>SF-36 is a standardized participant-administered measure designed to evaluate 8 domains of functional health and well being with 2 components (physical health score [PH] and mental component score [MH]). Both scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.</description>
          <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes of the PH score from baseline, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.740" spread="8.929"/>
                    <measurement group_id="O2" value="1.957" spread="8.691"/>
                    <measurement group_id="O3" value="6.943" spread="9.347"/>
                    <measurement group_id="O4" value="2.923" spread="8.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of the PH score from baseline, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.763" spread="9.311"/>
                    <measurement group_id="O2" value="3.647" spread="8.886"/>
                    <measurement group_id="O3" value="7.457" spread="9.115"/>
                    <measurement group_id="O4" value="0.992" spread="10.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of the PH score from baseline, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.117" spread="8.731"/>
                    <measurement group_id="O2" value="1.820" spread="10.255"/>
                    <measurement group_id="O3" value="7.804" spread="8.574"/>
                    <measurement group_id="O4" value="3.465" spread="9.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of the MH score from baseline, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.633" spread="7.020"/>
                    <measurement group_id="O2" value="7.387" spread="9.915"/>
                    <measurement group_id="O3" value="4.196" spread="11.329"/>
                    <measurement group_id="O4" value="3.327" spread="12.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of the MH score from baseline, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.773" spread="9.176"/>
                    <measurement group_id="O2" value="8.443" spread="10.287"/>
                    <measurement group_id="O3" value="6.364" spread="9.946"/>
                    <measurement group_id="O4" value="2.792" spread="9.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of the MH score from baseline, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.437" spread="8.939"/>
                    <measurement group_id="O2" value="8.693" spread="10.551"/>
                    <measurement group_id="O3" value="5.686" spread="9.925"/>
                    <measurement group_id="O4" value="3.004" spread="11.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Quality of Life Assessed by DLQI After 4, 8 and 12 Weeks of Treatment With BCD-085</title>
        <description>The Dermatology Life Quality Index (DLQI) is a 10-item self-reported survey, which addresses feelings, daily activities, leisure, work, school, personal relationships, and treatment. Each question was assessed using a 3-point scale, where score 3 means &quot;very much&quot;, score 2 means &quot;a lot&quot;, score 1 - &quot;a little&quot;, and score 0 - &quot;not at all&quot;. If more than two questions were left unanswered, the questionnaire was considered invalid. A total score was calculated by summing the score of all items (total maximum score is 30; total minimum score is 0). The higher score representing greater health-related quality of life impairment.&#xD;
The mean score change was estimated as the difference between the DLQI at baseline and at the assessed visit (the baseline score was subtracted from the visit score).</description>
        <time_frame>Week 4, Week 8, Week 12</time_frame>
        <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Quality of Life Assessed by DLQI After 4, 8 and 12 Weeks of Treatment With BCD-085</title>
          <description>The Dermatology Life Quality Index (DLQI) is a 10-item self-reported survey, which addresses feelings, daily activities, leisure, work, school, personal relationships, and treatment. Each question was assessed using a 3-point scale, where score 3 means &quot;very much&quot;, score 2 means &quot;a lot&quot;, score 1 - &quot;a little&quot;, and score 0 - &quot;not at all&quot;. If more than two questions were left unanswered, the questionnaire was considered invalid. A total score was calculated by summing the score of all items (total maximum score is 30; total minimum score is 0). The higher score representing greater health-related quality of life impairment.&#xD;
The mean score change was estimated as the difference between the DLQI at baseline and at the assessed visit (the baseline score was subtracted from the visit score).</description>
          <population>The efficacy analysis was planned to include all patients who received at least one dose of BCD-085/placebo and who attended at least one post-dose visit. The efficacy population comprised of 114 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes of the DLQI score, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.833" spread="7.292"/>
                    <measurement group_id="O2" value="-9.000" spread="6.988"/>
                    <measurement group_id="O3" value="-8.143" spread="5.662"/>
                    <measurement group_id="O4" value="-4.308" spread="7.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of the DLQI score, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.967" spread="7.462"/>
                    <measurement group_id="O2" value="-11.133" spread="7.380"/>
                    <measurement group_id="O3" value="-10.679" spread="5.157"/>
                    <measurement group_id="O4" value="-4.846" spread="7.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of the DLQI score, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.700" spread="7.901"/>
                    <measurement group_id="O2" value="-12.333" spread="7.369"/>
                    <measurement group_id="O3" value="-10.107" spread="7.809"/>
                    <measurement group_id="O4" value="-5.654" spread="7.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of AE/SAE</title>
        <description>Number of participants with AEs and SAEs was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
        <time_frame>14 weeks</time_frame>
        <population>The safety analysis included all patients who received at least one dose of BCD-085 (31 in Arm 1, 30 in Arm 2, and 28 in each of arms 3 and 4, with the total number n=117).</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of AE/SAE</title>
          <description>Number of participants with AEs and SAEs was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
          <population>The safety analysis included all patients who received at least one dose of BCD-085 (31 in Arm 1, 30 in Arm 2, and 28 in each of arms 3 and 4, with the total number n=117).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs/SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy-related AEs/SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs, grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy-related AEs, grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Local Reactions</title>
        <description>Number of participants with local reactions was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
        <time_frame>14 weeks</time_frame>
        <population>The safety analysis included all patients who received at least one dose of BCD-085 (31 in Arm 1, 30 in Arm 2, and 28 in each of arms 3 and 4, with the total number n=117).</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Local Reactions</title>
          <description>Number of participants with local reactions was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
          <population>The safety analysis included all patients who received at least one dose of BCD-085 (31 in Arm 1, 30 in Arm 2, and 28 in each of arms 3 and 4, with the total number n=117).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of AE/SAE Grade 4 CTCAE 4.03</title>
        <description>Number of participants with AEs/SAEs grade 4 CTCAE 4.03 was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
        <time_frame>14 weeks</time_frame>
        <population>The safety analysis included all patients who received at least one dose of BCD-085 (31 in Arm 1, 30 in Arm 2, and 28 in each of arms 3 and 4, with the total number n=117).</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of AE/SAE Grade 4 CTCAE 4.03</title>
          <description>Number of participants with AEs/SAEs grade 4 CTCAE 4.03 was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
          <population>The safety analysis included all patients who received at least one dose of BCD-085 (31 in Arm 1, 30 in Arm 2, and 28 in each of arms 3 and 4, with the total number n=117).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs, grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Withdrawal Due to AE/SAE</title>
        <description>Number of participants who withdrew due to AEs/SAEs was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
        <time_frame>14 weeks</time_frame>
        <population>The safety analysis included all patients who received at least one dose of BCD-085 (31 in Arm 1, 30 in Arm 2, and 28 in each of arms 3 and 4, with the total number n=117).</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-085, 40 mg</title>
            <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O2">
            <title>BCD-085, 80 mg</title>
            <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O3">
            <title>BCD-085, 120 mg</title>
            <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Withdrawal Due to AE/SAE</title>
          <description>Number of participants who withdrew due to AEs/SAEs was presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.</description>
          <population>The safety analysis included all patients who received at least one dose of BCD-085 (31 in Arm 1, 30 in Arm 2, and 28 in each of arms 3 and 4, with the total number n=117).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 month</time_frame>
      <desc>The safety analysis included the data from all patients received at least one dose of BCD-085/placebo. 3 patients were removed from the safety analysis because they recalled their informed consent before the first dose.&#xD;
Aggravation, worsening, and symptoms of the plaque psoriasis were not reportable as AEs. If hospitalization was due to aggravation or worsening of psoriasis it was not reportable as an SAE.</desc>
      <group_list>
        <group group_id="E1">
          <title>BCD-085, 40 mg</title>
          <description>Patients will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
        </group>
        <group group_id="E2">
          <title>BCD-085, 80 mg</title>
          <description>Patients will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
        </group>
        <group group_id="E3">
          <title>BCD-085, 120 mg</title>
          <description>Patients will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
BCD-085</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Patients will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>ESR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Total bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ARVI</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Conjuctivitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>LDH increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial BP increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Systolic BP increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nikiforova Aleksandra</name_or_title>
      <organization>BIOCAD</organization>
      <phone>+7(812) 380 49 33 ext 6254</phone>
      <email>nikiforovaan@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

